An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face.
Clin Dermatol. 2009 Nov-Dec; 27(6 Suppl):S48-53.CD

Abstract

The treatment of seborrheic dermatitis includes topical antifungal agents to eradicate Malassezia spp, corticosteroids, which treat the inflammatory component of the disease and keratolytics which remove scale and crust. This study compared the efficacy of a nonsteroidal topical cream and a low-potency topical corticosteroid for the treatment of mild to moderate seborrheic dermatitis of the face in 77 volunteers randomized to twice-daily treatment with nonsteroidal cream or corticosteroid cream for up to 28 days. If the individual was rated clear by day 14, the study drug was collected and the participant was told not to use any topical products on the previously treated areas until after the 28-day follow-up visit. Both treatments were similarly effective in reducing disease severity, with approximately 90% of participants clearing or almost clear during the study. Both treatments demonstrated significant reductions in erythema, scaling, and pruritus (P < .0001). Safety in both groups was rated as excellent in more than 90%. Those using the nonsteroidal cream who cleared after 14 days of treatment were more likely to remain clear than were participants using the corticosteroid cream (P = .0173). Investigator global assessments of improvement found both study agents were essentially the same, and participants in both groups achieved clinically important improvement.

Links

Publisher Full Text

Aggregator Full Text

Authors+Show Affiliations

Elewski B

Department of Dermatology, University of Alabama at Birmingham School of Medicine, Ste 414, 700 18th St S, Birmingham, AL 35233-3805, USA. beelewski@aol.com

MeSH

Administration, TopicalAntifungal AgentsDermatitis, SeborrheicDermatologic AgentsDouble-Blind MethodDrug Administration ScheduleEmollientsFacial DermatosesFemaleHumansMaleMiddle AgedOintments

Pub Type(s)

Comparative Study

Journal Article

Multicenter Study

Randomized Controlled Trial

Language

eng

PubMed ID

19878781

Citation

Elewski, Boni. "An Investigator-blind, Randomized, 4-week, Parallel-group, Multicenter Pilot Study to Compare the Safety and Efficacy of a Nonsteroidal Cream (Promiseb Topical Cream) and Desonide Cream 0.05% in the Twice-daily Treatment of Mild to Moderate Seborrheic Dermatitis of the Face." Clinics in Dermatology, vol. 27, no. 6 Suppl, 2009, pp. S48-53.

Elewski B. An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face. Clin Dermatol. 2009;27(6 Suppl):S48-53.

Elewski, B. (2009). An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face. Clinics in Dermatology, 27(6 Suppl), S48-53. https://doi.org/10.1016/j.clindermatol.2009.09.002

Elewski B. An Investigator-blind, Randomized, 4-week, Parallel-group, Multicenter Pilot Study to Compare the Safety and Efficacy of a Nonsteroidal Cream (Promiseb Topical Cream) and Desonide Cream 0.05% in the Twice-daily Treatment of Mild to Moderate Seborrheic Dermatitis of the Face. Clin Dermatol. 2009 Nov-Dec;27(6 Suppl):S48-53. PubMed PMID: 19878781.

* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face. A1 - Elewski,Boni, PY - 2009/11/3/entrez PY - 2009/11/13/pubmed PY - 2010/2/23/medline SP - S48 EP - 53 JF - Clinics in dermatology JO - Clin Dermatol VL - 27 IS - 6 Suppl N2 - The treatment of seborrheic dermatitis includes topical antifungal agents to eradicate Malassezia spp, corticosteroids, which treat the inflammatory component of the disease and keratolytics which remove scale and crust. This study compared the efficacy of a nonsteroidal topical cream and a low-potency topical corticosteroid for the treatment of mild to moderate seborrheic dermatitis of the face in 77 volunteers randomized to twice-daily treatment with nonsteroidal cream or corticosteroid cream for up to 28 days. If the individual was rated clear by day 14, the study drug was collected and the participant was told not to use any topical products on the previously treated areas until after the 28-day follow-up visit. Both treatments were similarly effective in reducing disease severity, with approximately 90% of participants clearing or almost clear during the study. Both treatments demonstrated significant reductions in erythema, scaling, and pruritus (P < .0001). Safety in both groups was rated as excellent in more than 90%. Those using the nonsteroidal cream who cleared after 14 days of treatment were more likely to remain clear than were participants using the corticosteroid cream (P = .0173). Investigator global assessments of improvement found both study agents were essentially the same, and participants in both groups achieved clinically important improvement. SN - 1879-1131 UR - https://www.unboundmedicine.com/medline/citation/19878781/An_investigator_blind_randomized_4_week_parallel_group_multicenter_pilot_study_to_compare_the_safety_and_efficacy_of_a_nonsteroidal_cream__Promiseb_Topical_Cream__and_desonide_cream_0_05_in_the_twice_daily_treatment_of_mild_to_moderate_seborrheic_dermatitis_of_the_face_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0738-081X(09)00192-8 DB - PRIME DP - Unbound Medicine ER -

Tags